Chronic Kidney Disease

Cystatin C, a filtration biomarker less influenced by muscle mass than creatinine, was associated with 20-year all-cause and cardiovascular mortality in a nationally representative US cohort. Associations persisted after adjustment for demographics, comorbi...

Cystatin C, an alternative filtration marker for kidney function, was associated with long-term all-cause and cardiovascular mortality in a general US cohort over 20 years, independent of demographics, comorbidities, and creatinine-based eGFR. The results s...

In a general US cohort, higher baseline cystatin C, a filtration biomarker independent of muscle mass, tracked with increased all-cause and cardiovascular mortality over 20 years. Associations persisted after adjustment for creatinine-based eGFR and risk fa...

Chronic kidney disease risk assessment is evolving as cystatin C, a filtration marker less affected by muscle mass than creatinine, shows a persistent association with 20-year all-cause and cardiovascular mortality in a representative US cohort. The signal ...

Chronic kidney disease after heart transplant remains common and progressive. The randomized DAPARHT trial evaluates dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, for renal protection in adult recipients versus control. The protocol emphasizes ...

The DAPARHT randomized controlled trial launches to test dapagliflozin for renal protection in heart transplant recipients at elevated risk of chronic kidney disease. The protocol evaluates kidney function trajectories, safety, and tolerability against stan...